Apogem Capital LLC Kezar Life Sciences, Inc. Transaction History

Apogem Capital LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$7.99 - $10.75 $4,849 - $6,525	-607 Reduced 0.65%	93,322 $804,000
Q2 2022 Aug 15, 2022	BUY	$4.58 - $17.13 $329,338 - $1.23 Million	71,908 Added 326.54%	93,929 $777,000
Q1 2022 May 16, 2022	SELL	$12.3 - $18.33 $61,561 - $91,741	-5,005 Reduced 18.52%	22,021 $366,000
Q4 2021 Feb 14, 2022	SELL	$7.44 - $16.72 $158,643 - $356,520	-21,323 Reduced 44.1%	27,026 $452,000
Q3 2021 Nov 15, 2021	SELL	$4.85 - $9.73 $148,017 - $296,949	-30,519 Reduced 38.7%	48,349 $418,000
Q2 2021 Aug 16, 2021	BUY	$4.93 - $6.46 $104,506 - $136,939	21,198 Added 36.76%	78,868 $428,000
Q1 2021 May 14, 2021	BUY	$5.24 - $6.99 $302,190 - $403,113	57,670 New	57,670 $344,000

38.4M

13.8K

600

Ticker KZR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,369,504
Market Cap $446M
Description
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical tria...

Get notified when there are updates to the investment portfolio of Apogem Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Apogem Capital LLC with notifications on news.